You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Litigation Details for Huawei Technologies, Co, Ltd v. Samsung Electronics Co, Ltd. (N.D. Cal. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Huawei Technologies, Co, Ltd v. Samsung Electronics Co, Ltd.
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Details for Huawei Technologies, Co, Ltd v. Samsung Electronics Co, Ltd. (N.D. Cal. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-05-24 External link to document
2016-05-24 168 Order 166 patent”); 8,812,848; 8,644,239 (“the ’239 patent”); 8,885,587; 8,885,583; 8,639,246…27 ’246 patent”); 8,412,197 (“the ’197 patent”); 8,996,003; and 8,724,613 (“the ’613 patent”). …26 Huawei has asserted U.S. Patent Nos. 8,369,278 (“the ’278 patent”); 8,416,892; 8,483,166 (“the …Samsung has asserted U.S. Patent Nos. 8,228,827, 8,315,195 (“the ’195 patent”), RE44,105, …8,457,588 (“the ’588 patent”), 8,509,350, 9,113,419, 8,619,726 (“the ’726 patent”), 8,761,130 External link to document
2016-05-24 191 Writ Issued U.S. Patent Nos. 8,369,278; 8,416,892; 8,483,166; 8,812,848; 8,644,239; 8,885,587; 8,885,583; 8,639,246;…standard-essential patents (“SEPS”). In addition, Huawei alleged that Samsung infringes eleven of its patents: U.S.…alleged that Huawei infringes nine of its patents: U.S. Patent Nos. 8,228,827; 8,315,195; RE44,105; 8,…that they infringe the patents asserted against them and contend that the patents asserted against them…art exists that anticipates the patented claims or renders the patented claims obvious. Huawei has alleged External link to document
2016-05-24 318 Huawei's Updated Election of Asserted Claims and Accused Products (REDACTE • U.S. Patent 8,416,892, claims 1, 10 9 • U.S. Patent 8,644,239, claims 7, 18 10…currently asserted 5 patents to 4, narrows its currently asserted patent claims to no more than 10…10 • U.S. Patent 8,885,587, claims 3, 9 11 • U.S. Patent 8,724,613, claims 1, 5 12…purposes of assessing 17 infringement of Huawei’s patents. Therefore, provided that the parties enter or …2016 25 March 2019 3:16-cv-02787 830 Patent Both District Court, N.D. California External link to document
2016-05-24 323 Notice (Other) . R1-072330 + US Patent App. Pub. No. 2007/0230600 21 U.S. Patent 8,644,239 22 … U.S. Patent 8,885,587 6 14. U.S. Patent No. 8,472,368 7 15. U.S. Patent No. 8,472,368…-070189 + US Patent App. Pub. No. 2007/0230600 16 4. R1-071471 + US Patent App. Pub. No.…6. R1-072330 19 7. US Patent No. 8,477,698 + US Patent App. Pub. No. 2007/0230600 20 …094545 + U.S. Patent No. 8,472,368 11 19. TS 36.213 v8.5.0 + R1-094545 + U.S. Patent No. 9,036,564 External link to document
2016-05-24 330 Motion to Strike Huawei patents 8,724,613 (“’613 patent”), 8,885,587 (“’587 patent”), 8,644,239 (“’239 patent”), 6 …and8,416,892 (“’892 patent”), and Samsung patents RE44,105 (“’105 patent”), 8,761,130 (“’130 7 patent”), 9,288,825…the ’105 patent. 7 D. Samsung’s ’130 Patent 8 Samsung’s ’130 patent relates to…9,288,825 (“’825 patent”), and 8,619,726 (“’726 patent”). 8 I. BACKGROUND 9 This Court… 4 contribution to the patent office during examination of the ’613 patent, which makes the contribution External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Huawei Technologies Co., Ltd. v. Samsung Electronics Co., Ltd. | 3:16-cv-02787

Last updated: July 28, 2025


Introduction

The legal dispute between Huawei Technologies Co., Ltd. and Samsung Electronics Co., Ltd. under case number 3:16-cv-02787 represents a significant patent infringement case within the high-tech telecommunications sector. This litigation underscores the ongoing intensities of patent rights assertions between industry giants amid the global push for advanced 4G and 5G technologies. This analysis provides a comprehensive overview of the case, with a focus on key claims, legal strategies, and implications for the telecommunications patent landscape.


Case Background

Filed in the United States District Court for the Northern District of California in 2016, Huawei accused Samsung of infringing multiple Huawei patents related to wireless communication technologies, including 4G LTE standards and related hardware components. Huawei sought declaratory relief, seeking damages and injunctive relief to prevent further patent infringement [1].

Samsung, countered by asserting its own patent rights and challenging Huawei’s patent assertions, leading to a complex cross-licensing dispute. The case reflects a broader pattern of patent litigations between these corporations and the persistent ideological tension: innovation versus patent assertion and enforcement in telecommunications.


Core Patent Disputes and Claims

Huawei’s Patent Allegations

Huawei’s complaint primarily targeted Samsung’s mobile devices, citing specific patents related to:

  • LTE network handling and data processing technology
  • Antenna design and signal processing
  • Battery management and power optimization features

Huawei claimed Samsung’s devices infringe several of Huawei’s patents, which cover essential elements of LTE communications standardization, critical for 4G technology deployment.

Samsung’s Defense

Samsung’s defense comprised multiple strategies:

  • Non-infringement argument, asserting that their devices do not utilize Huawei’s patented technology.
  • Validity attacks on Huawei’s patents, claiming prior art undermines patent originality.
  • Counterclaims for patent infringement, including assertions of Samsung’s patents relating to hardware components.

Counterclaims and Cross-Licensing

The case evolved into a negotiation of licensing terms, with both sides engaging in cross-licensing arrangements to mitigate litigation risks. Samsung alleged Huawei’s patents lacked validity and that some were standards-essential patents (SEPs), which require FRAND (Fair, Reasonable, and Non-Discriminatory) licensing practices.


Legal Proceedings and Timeline

  • 2016: Complaint filed by Huawei, initiating the litigation.
  • 2017–2019: Discovery phase, with extensive depositions, claim construction hearings, and evidentiary exchanges.
  • 2020: Summary judgment motions filed, mostly focusing on patent validity and infringement claims.
  • 2021: Court ruling largely favored Samsung on several patent claims, dismissing some of Huawei’s assertions due to lack of infringement or prior art rebuttals.

The case has historically demonstrated the high complexity of patent litigation within the domain of telecommunication standards, where patent validity, essentiality, and FRAND commitments are contentious points.


Legal and Industry Implications

Standard-Essential Patents and FRAND Obligations

A crucial aspect of this litigation pertains to Standard-Essential Patents (SEPs). Both Huawei and Samsung hold SEPs essential to LTE standards. The case’s outcome influences how courts interpret and enforce FRAND obligations, which aim to foster fair licensing practices without stifling innovation.

Patent Validity and Prior Art Challenges

Samsung challenged Huawei’s patents’ novelty and non-obviousness, arguing some patents lacked inventive step due to prior disclosures. These arguments resonate with the broader global trend of scrutinizing patent validity under Section 102 and 103 of the U.S. Patent Act.

Impact on Patent Strategy

The dispute underscores the importance for telecom companies to safeguard their patent portfolios through rigorous patent prosecution and early licensing negotiations. It also illustrates the risks associated with asserting broad patents in crowded standards-compliant fields.

Settlement and Ongoing Litigation

While some aspects of the case proceeded to judgment, Huawei and Samsung engaged in multiple licensing negotiations, highlighting the importance of settlement strategies to avoid prolonged litigation costs and licensing uncertainties.


Analysis of Case Significance

This litigation exemplifies the tension in the tech industry between patent enforcement as a revenue strategy and the need for fair access to standards-essential technologies. The case demonstrates the courts’ role in balancing patent rights with standards compliance, emphasizing:

  • The importance of maintaining robust patent validity defenses against infringement allegations.
  • The need for clear licensing commitments to prevent antitrust concerns.
  • The potential for cross-licensing to mitigate extensive litigation costs.

Moreover, the case informs industry participants on the evolving judicial stance regarding SEP disputes, with particular attention to FRAND policies.


Key Takeaways

  • Patent validity remains a critical battleground in high-tech disputes, especially surrounding standards-essential patents (SEPs). Enforcement depends heavily on the ability to withstand prior art and inventive step challenges.

  • FRAND obligations are central to SEP licensing disputes. Courts are increasingly scrutinizing licensing practices to ensure compliance with fair, reasonable, and non-discriminatory commitments.

  • Cross-licensing arrangements mitigate litigation risk, encouraging industry innovators to negotiate licensing terms outside of protracted court battles.

  • Legal outcomes influence industry standards and innovation investment, emphasizing the need for rigorous patent prosecution and licensing strategies.

  • Case law from this dispute informs global standards enforcement, impacting patent litigation and licensing practices in the telecommunications sector.


Concluding Remarks

The Huawei v. Samsung litigation underscores the complex intersection of patent law, standards, and commercial strategy in the fast-evolving telecommunications industry. As 5G continues to roll out worldwide, disputes over essential patents and licensing practices are likely to increase, positioning judicial decisions and industry practices at the center of innovation and competition.


FAQs

  1. What are the primary legal issues in Huawei v. Samsung?
    The case centers around patent infringement allegations, validity challenges, and licensing obligations related to LTE standards and SEPs under FRAND commitments.

  2. How does this case impact SEP licensing in telecommunications?
    It highlights courts’ increasing focus on fair licensing practices, emphasizing that patent enforceability must align with standards compliance and FRAND obligations.

  3. Why are standard-essential patents contentious in litigation?
    Because SEPs are necessary for industry compliance with standards, disputes over licensing terms, validity, and patent essentiality directly affect market competition and innovation.

  4. What implications does this case have for patent strategy in telecom companies?
    It underscores the importance of diligent patent prosecution, validity defenses, and comprehensive licensing negotiations to avoid costly litigations and ensure enforceability.

  5. Will the Huawei-Samsung dispute influence future international patent litigation?
    Yes. The case’s rulings and legal reasoning will guide courts and industry stakeholders globally in handling SEP disputes, licensing obligations, and patent validity issues.


References

[1] Court docket: Huawei Technologies Co., Ltd. v. Samsung Electronics Co., Ltd., No. 3:16-cv-02787, U.S. District Court, Northern District of California.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.